{"id":"cd123","name":"CD123","symbol":"IL3RA","route":"/targets/cd123/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6012","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185291","uniprot":"https://www.uniprot.org/uniprotkb/P26951/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P26951","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3712987","open-targets":"https://platform.opentargets.org/target/ENSG00000185291","civic":"https://civicdb.org/genes/3563/summary","oncokb":"https://www.oncokb.org/gene/IL3RA","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL3RA","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=IL3RA","depmap":"https://depmap.org/portal/gene/IL3RA?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000185291-IL3RA","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3563","omim":"https://www.omim.org/entry/308385"}],"products":[{"id":"pivekimab-sunirine","name":"Pivekimab sunirine","status":"approved","modality":"ADC (anti-CD123 antibody, IGN payload)","route":"/drugs/pivekimab-sunirine/"},{"id":"tagraxofusp","name":"Tagraxofusp","status":"approved","modality":"Recombinant cytotoxin (IL-3 fused to diphtheria toxin)","route":"/drugs/tagraxofusp/"}],"trials":[{"id":"nct07581002","name":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","nct":"NCT07581002","phase":"2/3","status":"recruiting"},{"id":"nct06456463","name":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","nct":"NCT06456463","phase":"2","status":"active"},{"id":"nct03386513","name":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","nct":"NCT03386513","phase":"1/2","status":"active"},{"id":"nct04086264","name":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","nct":"NCT04086264","phase":"1/2","status":"active"}],"pathways":[],"companies":["abbvie","menarini","orum-therapeutics"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}